Product
Active Control
Aliases
Active Control (Shingrix)
4 clinical trials
7 indications
Indication
Healthy Control ParticipantsIndication
Gram-negative Bacterial InfectionIndication
Epigenetic AgingIndication
ImmunosenescenceIndication
Herpes ZosterIndication
Herpes zosterIndication
Infectious DiseaseClinical trial
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Three-way Crossover Study in Healthy Subjects to Evaluate the Next-day Residual Effects of 20 mg TasimelteonStatus: Completed, Estimated PCD: 2018-08-28
Clinical trial
A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial InfectionStatus: Active (not recruiting), Estimated PCD: 2024-06-12
Clinical trial
Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension TrialStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.Status: Active (not recruiting), Estimated PCD: 2024-02-23